BidaskClub upgraded shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a buy rating to a strong-buy rating in a research note published on Tuesday.

A number of other analysts have also recently issued reports on SCMP. Leerink Swann initiated coverage on Sucampo Pharmaceuticals in a research report on Monday, August 21st. They set an outperform rating and a $15.00 price objective on the stock. Mizuho cut Sucampo Pharmaceuticals from a buy rating to a neutral rating and lowered their price objective for the company from $14.00 to $12.00 in a research report on Tuesday, October 3rd. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 3rd. UBS lowered their price objective on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating on the stock in a research report on Thursday, October 12th. Finally, Maxim Group restated a buy rating and set a $23.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Thursday, November 2nd. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $16.60.

Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) opened at $17.00 on Tuesday. The stock has a market capitalization of $781.15, a P/E ratio of 11.47, a PEG ratio of 4.99 and a beta of 1.47. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a 1 year low of $9.30 and a 1 year high of $17.70.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. The business had revenue of $61.27 million for the quarter, compared to analysts’ expectations of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. Sucampo Pharmaceuticals’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.30 earnings per share. analysts predict that Sucampo Pharmaceuticals will post 1.12 EPS for the current year.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the sale, the insider now directly owns 52,023 shares in the company, valued at $858,379.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.13% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Louisiana State Employees Retirement System boosted its stake in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 100 shares in the last quarter. Arizona State Retirement System boosted its stake in Sucampo Pharmaceuticals by 1.6% in the second quarter. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 200 shares in the last quarter. Capstone Asset Management Co. boosted its stake in Sucampo Pharmaceuticals by 2.1% in the second quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 260 shares in the last quarter. Texas Permanent School Fund boosted its stake in Sucampo Pharmaceuticals by 2.2% in the second quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 398 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Sucampo Pharmaceuticals by 0.9% in the second quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 423 shares in the last quarter. 65.31% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/16/sucampo-pharmaceuticals-scmp-stock-rating-upgraded-by-bidaskclub.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Stock Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related stocks with our FREE daily email newsletter.